Singapore is investigating the efficacy and safety of Moderna, Pfizer-BioNTech’s COVID-19 vaccines for children 6 months and older

SINGAPORE: The Ministry of Health (MOH) and the COVID-19 Vaccination Expert Committee are currently studying the efficacy and safety of vaccines from Moderna and Pfizer-BioNTech in young children.

The study will examine the use of Moderna’s COVID-19 vaccine for children aged six months to five years and Pfizer-BioNTech’s vaccine for those aged six months to four years.

“We urge the respective vaccine manufacturers to obtain the relevant information to facilitate a risk-benefit assessment of the use of these vaccines in this age group,” the Ministry of Health said Monday, June 20 in response to questions from the public. media.

The United States Centers for Disease Control and Prevention on Saturday recommended COVID-19 vaccines for children as young as six months old, allowing a nationwide rollout to begin next week. The CDC’s decision came after a panel of advisers voted to recommend COVID-19 vaccines for these children.

The U.S. Food and Drug Administration on Friday authorized Moderna’s vaccine for children aged six months to five years and Pfizer-BioNTech’s vaccine for children aged six months to four years. Pfizer-BioNTech’s vaccine is already licensed for children over the age of five in the United States.

Sara H. Byrd